Browse > Article

Effect of Bifidobacterium Cell Fractions on IL-6 Production in RAW 264.7 Macrophage Cells  

Lee, Byung-Hee (Department of Food Science and Nutrition, Seoul National University)
Ji, Geun-Eog (Research Center, BIFIDO Co., LTD.)
Publication Information
Journal of Microbiology and Biotechnology / v.15, no.4, 2005 , pp. 740-744 More about this Journal
Abstract
Bifidobacterium has been previously shown to potentiate immune function, which was mediated through the stimulation of cytokine production by macrophage. This study was performed to further characterize the effective component of Bifidobacterium by measuring the level of interleukin (IL)-6 cytokine using the RAW 264.7 murine cell line as a macrophage model. RAW 264.7 cells were cultured for 24 h in the presence of whole cells (WCs), cell walls (CWs), and cell-free extracts (CFEs) from various strains of Bifidobacterium and other lactic acid bacteria at various concentrations. The most effective component was different depending on the strains and the concentrations used. When tested with each cell fraction from Bifidobacterium sp. BGN4, heat treatment of the cell fractions lowered the production of IL-6. Synergistic effect was obtained, especially when CWs and CFEs were combined. Sonicated WCs stimulated IL-6 production more than intact WCs. The in vitro approaches employed here should be useful in further characterization of the effects of Bifidobacterium on gastrointestinal and systemic immunity.
Keywords
Bifidobacterium; IL-6; macrophage; cell fractions;
Citations & Related Records

Times Cited By Web Of Science : 9  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Abbas, A. K., A. H. Lichtman, and J. S. Pobe. 1994. Cytokines, p. 240. In Cellular and Molecular Immunology. 2nd Ed. W. B. Saunders Co., Philadelphia, PA
2 Choi, Y J., C. J. Kim, S. Y Park, Y T. Ko, H. K. Jeong, and G E. Ji. 1996. Growth and beta-glucosidase activity of Bifidobacterium. J. Microbiol. Biotechnol. 6: 255-259
3 Kanauchi, O., K. Mitsuyama, Y Araki, and A. Andoh. 2003. Modification of intestinal flora in the treatment of int1ammatory bowel disease. Curr. Pharm. Res. 9: 336-346
4 Lammers, K. M., P. Brigidi, B. Vitali, P. Gionchetti, F. Rizzello, E. Caramelli, D. Matteuzzi, and M. Campieri. 2003. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol. Med. Microbiol. 38: 165-172   DOI   ScienceOn
5 Park, S. Y., G. E. Ji, Y. T. Ko, H. K. Jung, Z. Ustunol, and J. J. Pestka. 1999. Potentiation of hydrogen peroxide, nitric oxide, and cytokine production in RAW 264.7 macrophage cells exposed to human and commercial isolates of Bifidobacterium. Int. J. Food Microbiol. 46: 231-241   DOI   ScienceOn
6 Rafter, J. J. 1995. The role of lactic acid bacteria in colon cancer prevention. Scand. J. Gastroenterol. 30: 497-502   DOI   PUBMED   ScienceOn
7 Sekine, K., E. Watanabe-Sekine, J. Ohta, T. Toida, T. Tatsuki, T. Kawashima, and Y. Hashimoto. 1994. Induction and activation of tumoricidal cells in vivo and in vitro by the bacterial cell wall of Bifidobacterium infantis. Bifidobact. Microfl. 13: 65-77   DOI
8 Yasui, H. and M. Ohwaki. 1991. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J. Dairy Sci. 74: 1187-1195   DOI   ScienceOn
9 Sekine, K., J. Ohta, M. Onishi, T. Tatsuki, Y. Shimokawa, T. Toida, T. Kawashima, and Y. Hashimoto. 1995. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium in/antis. Biol. Pharm. Bull. 18: 148-153   DOI   ScienceOn
10 Mitsuoka, T. 1982. Recent trends in research on intestinal flora. Bifidobact. Microfl. 1: 3-24   DOI
11 Strober, W. 1991. Trypan blue exclusion test for cell viability, pp. A.3.3-4.ln J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology. Greene Pub. and Wiley-Interscience, New York, U.S.A,
12 Park, M. S., H. W. Moon, and G. E. Ji. 2003. Molecular characterization of plasmid from Bifidobacterium longum. J. Microbial. Biotechnol. 13: 457-461
13 Fernandes, C. F. and K. M. Shahani. 1990. Anticarcinogenic and immunological properties of dietary lactobacilli. J. Food Proto 53: 704- 710   DOI
14 Gomez, E., M. M. Melgar, G P. Silva, A Portoles, and I. Gil. 1988. Exocellular products from Bifidobacterium adolescentis as immunomodifiers in the Iymphoprohferative responses of mouse splenocytes. FEMS Microbiol. Lett. 56: 47-52   DOI
15 Kim, H. J., J. H. Kim, J. H. Son, H. J. Sea, S. J. Park, M. S. Paek, and S. K. Kim. 2004. Characterization of bacteriocin produced by Lactobacillus bulgaricus. J. Microbiol. Bioteclmol. 14: 503-508
16 Sasaki, T., S. Fukami, and S. Namioka. 1994. Enhanced resistance of mice to Escherichia coli infection induced by administration of peptidoglycan derived from Bifidobacterium thermophilum. J. Vet. Med. Sci. 53: 433-437
17 Yu, K. W., K. S. Shin, Y. M. Choi, and H. J. Suh. 2004. Macrophage stimulating activity of exo-biopolymer from submerged culture of Lentinus edodes with rice bran. J. Microbiol. Biotechnal. 14: 658-664
18 Lee, J., A. Ametani, A. Enomoto, Y. Sato, H. Motoshima, F. Ike, and S. Kaminogawa. 1993. Screening for the immunopotentiating activity of food microorganisms and enhancement of the immune response by Bifidobacterium adolescentis M101-4. Biosci. Biotech. Biochem. 57: 2127-2132   DOI
19 Namioka, S. 1985. Immunoresponsiveness of newborn piglets and peptidoglycan derived from Bifidobacterium. Bifidobact. Microfl. 4: 3-14   DOI
20 Hattori, K., A. Yamamoto, M. Sasai, S. Taniuchi, T. Kojima, Y Kobayashi, H. Iwamoto, K. Namba, and T. Yaeshima. 2003. Effects of administration of bifidobacteria on fecal microtlora and clinical symptoms in infants with atopic dermatitis. Arerugi 252: 20-30
21 Hughes, D. B. and D. G Hoover. 1991. Bifidobacterium: Their potential for use in American dairy products. Food Technol. 45: 74-83
22 Hatcher, G E. and R. S. Lambrecht. 1993. Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J. Dairy Sci. 76: 2485-2492   DOI   ScienceOn
23 Dong, W., J. I. Azcona-Olivera, K. H. Brooks, J. E. Linz, and J. J. Pestka. 1994. Elevated gene expression and production of interleukins 2, 4, 5, and 6 during exposure to vomitoxin (deoxynivalenol) and cycloheximide in the EL-4 thymoma. Toxicol. Appl. Pharmacol. 127: 282-290   DOI   ScienceOn
24 Hosono, A, J. Lee, A Ametani, M. Natsume, M. Hirayama, T. Adachi, and S. Kaminogawa. 1997. Characterization of a water-soluble polysaccharide fraction with immunopotentiating activity from Bifidobacterim adolescentis M 101-4. Biosci. Biotech. Biochem. 61: 312-316   DOI   ScienceOn
25 Ishikawa, H., I. Akedo, Y. Umesaki, R. Tanaka, A. lmaoka, and T. Otani. 2003. Randomized controlled trial ofthe effect of Bifidobacterium-fermented milk on ulcerative colitis. J. Am. Call. Nutr. 22: 256-263
26 Kim, I. H., M. S. Park, and G E. Ji. 2003. Characterization of adhesion of Bifidobacterium sp. BGN4 to human enterocytelike Caco-2 cells. J. Microbiol. Biotechnol. 13: 276-281
27 Miettinen, M., J. Vuopio-Varkila, and K. Varkila. 1996. Production of human necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect. Immun. 64: 5403-5405
28 Kado-Oka, Y, S. Fujiwara, and T. Hirota. 1991. Effects of Bifidobacterium cells on mitogenic response of splenocytes and several functions of phagocytes. Milchwissenshaft 46: 626-630
29 Akira, S., T. Taga, and T. Kishimoto. 1993. Interleukin-6 in biology and medicine. Adv. Immunol. 54: 1-78   DOI